Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCabarrou, Bastien
dc.contributor.authorGil Moreno, Antonio
dc.contributor.authorPerez Benavente, Maria Asuncion
dc.contributor.authorSpagnolo, Emanuela
dc.contributor.authorRychlik, Agnieszka
dc.contributor.authorAngeles, Martina Aida
dc.date.accessioned2022-04-25T14:59:20Z
dc.date.available2022-04-25T14:59:20Z
dc.date.issued2021-11
dc.identifier.citationAngeles MA, Cabarrou B, Gil-Moreno A, Pérez-Benavente A, Spagnolo E, Rychlik A, et al. Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer. J Gynecol Oncol. 2021 Nov;32(6):e78.
dc.identifier.issn2005-0399
dc.identifier.urihttps://hdl.handle.net/11351/7408
dc.descriptionCytoreduction Surgical Procedures; Neoadjuvant Therapy; Ovarian Neoplasms
dc.description.abstractObjective We sought to evaluate the impact on survival of tumor burden and surgical complexity in relation to the number of cycles of neoadjuvant chemotherapy (NACT) in patients with advanced ovarian cancer (OC) with minimal (CC-1) or no residual disease (CC-0). Methods This retrospective study included patients with International Federation of Gynaecology and Obstetrics IIIC–IV stage OC who underwent debulking surgery at 4 high-volume institutions between January 2008 and December 2015. We assessed the overall survival (OS) of primary debulking surgery (PDS group), early interval debulking surgery after 3–4 cycles of NACT (early IDS group) and delayed debulking surgery after 6 cycles (DDS group) with CC-0 or CC-1 according to peritoneal cancer index (PCI) and Aletti score. Results Five hundred forty-nine women were included: 175 (31.9%) had PDS, 224 (40.8%) early IDS and 150 (27.3%) DDS. Regardless of Aletti score, median OS after PDS was significantly higher than after early IDS or DDS, but the survival difference was higher in women with an Aletti score <8. Among patients with PCI ≤10, median OS after PDS was significantly higher than after early IDS or DDS. In women with PCI >10, there were no differences between PDS and early IDS, but DDS was associated with decreased OS. Conclusion The benefit of complete PDS compared with NACT was maximal in patients with a low complexity score. In patients with low tumor burden, there was a survival benefit of PDS over early IDS or DDS. In women with high tumor load, DDS impaired the oncological outcome.
dc.language.isoeng
dc.publisherKorean Society of Gynecologic Oncology & Colposcopy
dc.relation.ispartofseriesJournal of Gynecologic Oncology;32(6)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectOvaris - Càncer - Cirurgia
dc.subjectQuimioteràpia combinada
dc.subjectMarcadors tumorals
dc.subject.meshOvarian Neoplasms
dc.subject.mesh/surgery
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshTumor Burden
dc.titleEffect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3802/jgo.2021.32.e78
dc.subject.decsneoplasias ováricas
dc.subject.decs/cirugía
dc.subject.decsquimioterapia adyuvante
dc.subject.decscarga tumoral
dc.relation.publishversionhttps://doi.org/10.3802/jgo.2021.32.e78
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Angeles MA] Department of Surgical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole (IUCT-Oncopole), Toulouse, France. [Cabarrou B] Biostatistics Unit, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse Oncopole (IUCT-Oncopole), Toulouse, France. [Gil-Moreno A, Pérez-Benavente A] Servei d’Oncologia Ginecològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Spagnolo E] Gynecologic Oncology Unit, La Paz University Hospital, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain. [Rychlik A] Department of Gynaecologic Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
dc.identifier.pmid34431252
dc.identifier.wos000756151400007
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record